Idorsia Requests DEA Lift Controlled Substance Restrictions On Dual Orexin Receptor Antagonists For Insomnia
Executive Summary
Schedule IV classification for Idorsia’s Quviviq, along with Merck & Co’s Belsomra and Eisai’s Dayvigo, distorts the drug class’ benefit-risk profile relative to other insomnia treatments, which are prioritized for prescribing but carry higher risk of abuse and other adverse events, company says.
You may also be interested in...
Idorsia Makes Progress With Quviviq, But Needs Cash To Fund Big R&D And Launch Spending
Idorsia has a serious cashflow problem because of major R&D and drug launch commitments, but is banking on its blockbuster bets coming good, including two potential first-in-class cardiovascular drugs.
Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch
The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.
Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker